Robust immune responses are observed after one dose of BNT162b2 mRNA vaccine dose in SARS-CoV-2-experienced individuals.
Journal
Science translational medicine
ISSN: 1946-6242
Titre abrégé: Sci Transl Med
Pays: United States
ID NLM: 101505086
Informations de publication
Date de publication:
09 Feb 2022
09 Feb 2022
Historique:
pubmed:
8
12
2021
medline:
15
2
2022
entrez:
7
12
2021
Statut:
ppublish
Résumé
The use of coronavirus disease 2019 (COVID-19) vaccines will play the major role in helping to end the pandemic that has killed millions worldwide. COVID-19 vaccines have resulted in robust humoral responses and protective efficacy in human trials, but efficacy trials excluded individuals with a prior diagnosis of COVID-19. As a result, little is known about how immune responses induced by mRNA vaccines differ in individuals who recovered from COVID-19. Here, we evaluated longitudinal immune responses to two-dose BNT162b2 mRNA vaccination in 15 adults who had experienced COVID-19, compared to 21 adults who did not have prior COVID-19. Consistent with prior studies of mRNA vaccines, we observed robust cytotoxic CD8
Identifiants
pubmed: 34874183
doi: 10.1126/scitranslmed.abi8961
pii: 10.1126/scitranslmed.abi8961
pmc: PMC9248013
mid: NIHMS1800466
doi:
Substances chimiques
Antibodies, Viral
0
COVID-19 Vaccines
0
Spike Glycoprotein, Coronavirus
0
Vaccines, Synthetic
0
mRNA Vaccines
0
BNT162 Vaccine
N38TVC63NU
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
eabi8961Subventions
Organisme : NIAID NIH HHS
ID : U01 AI047996
Pays : United States
Organisme : NHLBI NIH HHS
ID : R01 HL125816
Pays : United States
Organisme : NIAID NIH HHS
ID : K08 AI114852
Pays : United States
Organisme : NIAID NIH HHS
ID : U19 AI082630
Pays : United States
Organisme : NIAID NIH HHS
ID : R21 AI110830
Pays : United States
Organisme : NIAID NIH HHS
ID : R21 AI137752
Pays : United States
Organisme : NIAID NIH HHS
ID : UM1 AI148574
Pays : United States
Organisme : NIAID NIH HHS
ID : T32 AI074492
Pays : United States
Organisme : NIAID NIH HHS
ID : R01 AI158617
Pays : United States
Commentaires et corrections
Type : UpdateOf
Références
N Engl J Med. 2020 Oct 15;383(16):1544-1555
pubmed: 32722908
Sci Adv. 2021 Mar 19;7(12):
pubmed: 33608249
Sci Immunol. 2017 Jan 27;2(7):
pubmed: 28783670
Proc Natl Acad Sci U S A. 2016 Mar 8;113(10):2702-7
pubmed: 26908875
Mol Ther. 2017 Jun 7;25(6):1316-1327
pubmed: 28457665
Immunity. 2019 May 21;50(5):1132-1148
pubmed: 31117010
Lancet Infect Dis. 2021 Jan;21(1):52-58
pubmed: 33058797
Cell. 2021 Feb 18;184(4):861-880
pubmed: 33497610
Cell Death Differ. 2021 Feb;28(2):626-639
pubmed: 33479399
Sci Rep. 2016 May 27;6:26494
pubmed: 27231124
Immunity. 2014 Oct 16;41(4):529-42
pubmed: 25367570
Nature. 2020 Oct;586(7830):594-599
pubmed: 32998157
Sci Immunol. 2017 Feb;2(8):
pubmed: 28620653
Cell. 2021 Apr 1;184(7):1671-1692
pubmed: 33743212
N Engl J Med. 2020 Nov 12;383(20):1920-1931
pubmed: 32663912
Front Physiol. 2021 Jan 12;11:571416
pubmed: 33510644
Cell. 2020 Jun 25;181(7):1489-1501.e15
pubmed: 32473127
Annu Rev Immunol. 2020 Apr 26;38:315-340
pubmed: 31986068
Sci Transl Med. 2013 Mar 13;5(176):176ra32
pubmed: 23486778
Acta Pharmacol Sin. 2020 Sep;41(9):1141-1149
pubmed: 32747721
Cell Host Microbe. 2016 May 11;19(5):713-9
pubmed: 27107939
Immunity. 2013 Oct 17;39(4):758-69
pubmed: 24035365
Cell. 2020 Nov 12;183(4):996-1012.e19
pubmed: 33010815
Vaccine. 2009 Jan 22;27(4):505-12
pubmed: 19022319
Nature. 2021 Aug;596(7870):109-113
pubmed: 34182569
J Immunol. 2016 Aug 1;197(3):983-93
pubmed: 27342848
Immunity. 2020 Dec 15;53(6):1281-1295.e5
pubmed: 33296685
Clin Interv Aging. 2012;7:55-64
pubmed: 22393283
Nature. 2020 Oct;586(7827):127-132
pubmed: 32866963
Nature. 2020 Oct;586(7830):589-593
pubmed: 32785213
J Clin Invest. 2019 Jul 2;129(8):3185-3200
pubmed: 31264971
Immunity. 2020 Oct 13;53(4):724-732.e7
pubmed: 32783919
Lancet. 2021 Apr 17;397(10283):1459-1469
pubmed: 33844963
Nature. 2021 Feb;590(7847):630-634
pubmed: 33276369
Ann Rheum Dis. 2021 Oct;80(10):1339-1344
pubmed: 34035003
J Immunol Methods. 1986 Jan 22;86(1):83-7
pubmed: 3944471
N Engl J Med. 2021 Feb 4;384(5):403-416
pubmed: 33378609
J Immunol. 2021 Aug 15;207(4):1033-1043
pubmed: 34321231
Lancet Infect Dis. 2020 May;20(5):533-534
pubmed: 32087114
Science. 2020 Oct 2;370(6512):89-94
pubmed: 32753554
Bioinformatics. 2010 Jan 1;26(1):139-40
pubmed: 19910308
Cell. 2015 Jul 2;162(1):184-97
pubmed: 26095251
Nat Commun. 2018 May 1;9(1):1758
pubmed: 29717110
Nat Rev Drug Discov. 2018 Apr;17(4):261-279
pubmed: 29326426
Lancet Infect Dis. 2020 Aug;20(8):e192-e197
pubmed: 32539990
Front Immunol. 2017 Nov 13;8:1539
pubmed: 29181005
Science. 2021 Feb 5;371(6529):
pubmed: 33408181
N Engl J Med. 2020 Dec 17;383(25):2427-2438
pubmed: 32991794
Proc Natl Acad Sci U S A. 2014 Nov 4;111(44):15798-803
pubmed: 25331901
Immunity. 2018 Oct 16;49(4):725-739.e6
pubmed: 30314758
PLoS Pathog. 2019 Nov 4;15(11):e1007634
pubmed: 31682641
JAMA Intern Med. 2020 Nov 1;180(11):1546-1549
pubmed: 32986099
Sci Transl Med. 2011 Jun 1;3(85):85ra48
pubmed: 21632986
Clin Vaccine Immunol. 2010 Jul;17(7):1055-65
pubmed: 20463105
Front Immunol. 2018 Oct 22;9:2421
pubmed: 30405620
Nat Commun. 2020 Sep 11;11(1):4566
pubmed: 32917903
Science. 2020 Aug 14;369(6505):812-817
pubmed: 32434946
J Immunol. 2014 Oct 1;193(7):3528-37
pubmed: 25172499
Nat Immunol. 2016 Oct;17(10):1226-34
pubmed: 27525369
Clin Diagn Lab Immunol. 1998 Nov;5(6):799-803
pubmed: 9801337
Sci Immunol. 2021 Apr 15;6(58):
pubmed: 33858945
Annu Rev Immunol. 2018 Apr 26;36:279-308
pubmed: 29345964
Nature. 2021 Jul;595(7867):421-425
pubmed: 34030176
N Engl J Med. 2020 Dec 31;383(27):2603-2615
pubmed: 33301246
N Engl J Med. 2020 Dec 17;383(25):2439-2450
pubmed: 33053279
Science. 2017 Jan 27;355(6323):395-398
pubmed: 28126818
Nature. 2021 Jul;595(7868):572-577
pubmed: 34044428
Clin Infect Dis. 2021 Nov 2;73(9):e2946-e2951
pubmed: 32840608
Cell Rep Med. 2021 May 07;2(5):100262
pubmed: 34095875